

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	2752897
<b>Application Number:</b>	09612914
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	9512
<b>Title of Invention:</b>	Recombinant anti-CD4 antibodies for human therapy
<b>First Named Inventor/Applicant Name:</b>	Nabil Hanna
<b>Customer Number:</b>	27499
<b>Filer:</b>	Thomas A. Cawley Jr./John McKeague
<b>Filer Authorized By:</b>	Thomas A. Cawley Jr.
<b>Attorney Docket Number:</b>	037003-0275543
<b>Receipt Date:</b>	23-JAN-2008
<b>Filing Date:</b>	10-JUL-2000
<b>Time Stamp:</b>	16:00:39
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$460
RAM confirmation Number	1099
Deposit Account	033975
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Application Data Sheet	037003_0275543_applicatio n_data_sheet.pdf	87637	no	3
			25a9e29dcc2c81c9372dccc1fc85904713967190		
Warnings:					
Information:					
This is not an USPTO supplied ADS fillable form					
2	Rule 130, 131 or 132 Affidavits	037003_0275543_biological _deposit_declaration.pdf	68221	no	2
			34944b23e7e14abb7bac5faa9a747f920f949927		
Warnings:					
Information:					
3	Miscellaneous Incoming Letter	037003_0275543_biological _deposit_ATCC.pdf	46520	no	1
			7f61205744c2e10d3308b102b3de37def3f115c2		
Warnings:					
Information:					
4	Drawings-only black and white line drawings	037003_0275543_replacem ent_drawings.pdf	558736	no	17
			9d03e0b0d886c1402c01dbde5cb783bfa1360122		
Warnings:					
Information:					
5	CRF Statement Paper and CRF are the same	037003_0275543_sequence _statement.pdf	60803	no	1
			5d4ef77627cf0948947b74c9a0ff6e0ff45ce6bf		
Warnings:					
Information:					
6	Sequence Listing	037003_0275543_substitute _sequence_listing_paper.pdf	790920	no	31
			7fb3ab687290f1bcb5539d891c354f70ef2742e5		
Warnings:					
Information:					
7	Sequence Listing (Text File)	037003_0275543_sequence _listing_text_file.txt	58238	no	0
Warnings:					
Information:					
8	Terminal Disclaimer Filed	037003_0275543_terminal disclaimer_copending_applic ation.pdf	105260	no	2
			0e78474ae957a5191c59e8f4662c636ce01ea5ea		
Warnings:					
Information:					

9		037003_0275543_amendme nt_and_response.pdf	114158  599a24bd090aa2cffe5121d6a420b8b 9fba97a	yes	11
	<b>Multipart Description/PDF files in .zip description</b>				
	<b>Document Description</b>		<b>Start</b>	<b>End</b>	
	Amendment - After Non-Final Rejection		1	1	
	Drawings-only black and white line drawings		2	2	
	Specification		3	6	
	Applicant Arguments/Remarks Made in an Amendment		7	11	
<b>Warnings:</b>					
<b>Information:</b>					
10	Terminal Disclaimer Filed	037003_0275543_terminal_ disclaimer_prior_patent.pdf	73862  c2a80b21fe80c88b6a47cd6ac735f5102 31bf0d7	no	1
<b>Warnings:</b>					
<b>Information:</b>					
11	Fee Worksheet (PTO-06)	fee-info.pdf	8154  9e6f772588823b79c2cffi484a6ad140fd c0aca85	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			1972509		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>  If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					